Dr. Gunilla Enblad is a Senior Consultant in Oncology since 2000 and was Head of Department at the
- We are proud to have Gunilla Enblad as a scientific advisor and principal investigator in the upcoming clinical phase I/II study in blood cancer, which we plan to start next year. Gunilla's experience in the field will be very valuable, in everything from study design to scientific advice, says
Gunilla Enblad is a member of the Swedish Hodgkin lymphoma group since many years and acted as their Chairman between 2004 and 2013. Enblad's current research is focused on CAR T-cell therapy and in 2014 she treated the first patient in
During the second half of 2022, Elicera intends to start a clinical phase I/II study with the drug candidate ELC-301 for the treatment of B-cell lymphoma in which Gunilla Enblad will act as principal investigator.
About ELC-301
ELC-301 a CD20-directed CAR T-cell therapy for the treatment of B-cell lymphoma. ELC-301 has been armed with the company's iTANK-platform for activation of CD8 + killer T-cells against the whole set of relevant target antigens on tumor cells, thus generating a powerful parallel immune response against cancer. A clinical phase I/II study is expected to be initiated during the second half of 2022 in collaboration with
For further information please contact:
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
About
For more information, please visit www.elicera.com
https://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-appoints-professor-gunilla-enblad--key-opinion-leader-within-the-fields-of-car-,c3437809
https://mb.cision.com/Main/20218/3437809/1484382.pdf
(c) 2021 Cision. All rights reserved., source